New Evidence Update

PDF cover

PCSK9 Inhibitors: New Evidence Update

Following the March 2017 release of new clinical evidence on evolocumab (Repatha®, Amgen) from the FOURIER trial, the Institute for Clinical and Economic Review (ICER) has issued a New Evidence Update using those data to revise analyses of the drug’s long-term cost-effectiveness and the value-based price benchmark.

An earlier version of this document, posted on June 13, 2017, contained only clinical effectiveness analyses. This updated version contains both clinical and economic analyses. 


View All Materials on this Topic or Go Back to View More Materials